Nombre del producto:3-chloropropanoyl chloride

IUPAC Name:3-chloropropanoyl chloride

CAS:625-36-5
Fórmula molecular:C3H4Cl2O
Pureza:95%+
Número de catálogo:CM326224
Peso molecular:126.96

Unidad de embalaje Stock disponible Precio($) Cantidad
CM326224-1000g 1-2 Weeks ƥƥ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :625-36-5
Fórmula molecular:C3H4Cl2O
Punto de fusión:-
Código de sonrisas:O=C(Cl)CCCl
Densidad:
Número de catálogo:CM326224
Peso molecular:126.96
Punto de ebullición:
Nº Mdl:MFCD00000747
Almacenamiento:Keep in a tight container and store in a cool place

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Belzutifan
On September 19, MSD announced that the U.S. FDA has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for Welireg (Belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC). Welireg was the first HIF-2α inhibitor therapy approved in the U.S. and is currently approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.